Mark Mosteller, Chief Financial Officer and Henry Doggrell, General Counsel of GTx, Inc.,
Rings The NASDAQ Stock Market Closing Bell

Friday, September 1, 2006
at NASDAQ's MarketSite
in New York City.

GTx, Inc.
[GTXI]

Mark Mosteller, Chief Financial Officer and Henry Doggrell, General Counsel of GTx, Inc. (GTXI), presides over the closing bell to recognize Prostate Cancer Awareness Month.

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health.
GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for muscle wasting and bone loss indications. Ostarine is currently being evaluated in a Phase II clinical trial in 120 elderly men and postmenopausal women. GTx expects to have data from the Phase II ostarine trial in the fourth quarter of 2006. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 9/1/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: and Henry Doggrell, General Counsel of GTx, Inc. (GTXI), signs in at the Closing Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.